FDA finally approves Sandoz's Neulasta biosimilar, but will ...

The FDA has approved Sandoz’s pegfilgrastim biosimilar, a cheaper version of Amgen’s long-lasting and big-selling white blood cell booster Neulasta.

Daiichi Sankyo takes Seattle Genetics to court as battle ove...

Big-selling drugs often spark legal bunfights as companies squabble over who did what during the development process and what share of profits they deserve – and Daiichi Sankyo and AstraZen

Halozyme abandons cancer R&D as lead drug failed

Amgen pays $2.7bn to harness BeiGene’s China marketing muscl...

Finally, AZ claims a win with Imfinzi/tremelimumab cancer co...

Astellas gets EU approval for AML drug Xospata

The European Commission has approved Astellas’ Xospata (gilteritinib) for patients with relapsed or refractory FLT3-positive acute myeloid leukemia (AML), cementing its lead over a rival dr